share_log

Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress

Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress

默沙東宣佈將在2024年聯合歐洲胃腸病學周大會上展示Tulisokibart(Mk-7240)在潰瘍性結腸炎和克羅恩病中的長期療效和安全性數據。
Benzinga ·  09/26 06:47

Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress

默沙東宣佈將在2024年聯合歐洲胃腸病學周大會上展示Tulisokibart(Mk-7240)在潰瘍性結腸炎和克羅恩病中的長期療效和安全性數據。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論